← 483 OBSERVATION EXPLORER

FDA 483 OBSERVATION · #874 OF 1,000 MOST-CITED

Procedures and release criteria

FDA cited this observation 17 times across 16 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

BY PROGRAM AREA
Human Tissue for Transplantation17
BY FISCAL YEAR
FY20256
FY20241
FY20234
FY20221
FY20194
FY20171

How FDA worded it — real examples

Procedures including release criteria for activities relating to the receipt and distribution of HCT/Ps were not maintained, implemented, reviewed and revised.

K B Dental Products, Inc. · Anaheim, California · Human Tissue for Transplantation · 2025-07-31

Procedures including release criteria for activities relating to the distribution of HCT/Ps were not established and maintained.

SigmaGraft Inc · Fullerton, California · Human Tissue for Transplantation · 2025-04-25

Procedures including release criteria for activities relating to the receipt, shipment and distribution of HCT/Ps were not established and documented.

Novutech LLC · Doral, Florida · Human Tissue for Transplantation · 2025-02-06

Procedures including release criteria for activities relating to the receipt, shipment and distribution of HCT/Ps were not documented, implemented and followed.

MRT BIO Inc · La Palma, California · Human Tissue for Transplantation · 2024-12-13

Procedures including release criteria for activities relating to the receipt, shipment and distribution of HCT/Ps were not established.

Legacy Ortho LLC · Mason, Ohio · Human Tissue for Transplantation · 2024-10-29

Procedures including release criteria for activities relating to the receipt of HCT/Ps were not followed.

Alon Medical Technology · Flowood, Mississippi · Human Tissue for Transplantation · 2024-10-16

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Pharmaceutical quality system

Examples are a representative sample of FDA's published inspection observations. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →